Nazanene H Esfandiari1, David T Hughes2, David Reyes-Gastelum1, Kevin C Ward3, Ann S Hamilton4, Megan R Haymart1. 1. Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, Michigan. 2. Department of Surgery, Division of Endocrine Surgery, University of Michigan, Ann Arbor, Michigan. 3. Rollins School of Public Health, Department of Epidemiology, Emory University, Atlanta, Georgia. 4. Keck School of Medicine, Department of Preventive Medicine, University of Southern California, Los Angeles, California.
Abstract
CONTEXT: Nearly one-third of all thyroid cancers are ≤1 cm. OBJECTIVE: To determine diagnostic pathways for microcarcinomas vs larger cancers. DESIGN/SETTING/PARTICIPANTS: Patients from Georgia and Los Angeles Surveillance, Epidemiology, and End Results (SEER) registries with differentiated thyroid cancer diagnosed in 2014 or 2015 were surveyed. Survey data were linked to SEER data on tumor and treatment characteristics. Multivariable logistic regression analysis was performed. MAIN OUTCOME MEASURES: Method of nodule discovery; reason for thyroid surgery. RESULTS: Of patients who underwent surgery, 975 (38.2%) had cancers ≤1 cm, and 1588 cancers (61.8%) were >1 cm. The reported method of nodule discovery differed significantly between patients with cancers ≤1 cm and those with cancers >1 cm (P < 0.001). Cancer ≤1 cm was associated with nodule discovery on thyroid ultrasound (compared with other imaging, OR, 1.59; 95% CI, 1.21 to 2.10), older patient age (45 to 54 years vs ≤44, OR, 1.45; 95% CI, 1.16 to 1.82), and female sex (OR, 1.51; 95% CI, 1.22 to 1.87). Hispanic ethnicity (OR, 0.71; 95% CI, 0.57 to 0.89) and Asian race (OR, 0.67; 95% CI, 0.49 to 0.92) were negative correlates. Cancers ≤1 cm were associated with lower likelihood of surgery for a nodule suspicious or consistent with cancer (OR, 0.48; 95% CI, 0.40 to 0.57). CONCLUSION: Thyroid microcarcinomas are more likely to be detected by ultrasound and less likely to be associated with surgery scheduled for known thyroid cancer. Understanding diagnostic pathways allows for targeted interventions to decrease overdiagnosis and overtreatment.
CONTEXT: Nearly one-third of all thyroid cancers are ≤1 cm. OBJECTIVE: To determine diagnostic pathways for microcarcinomas vs larger cancers. DESIGN/SETTING/PARTICIPANTS: Patients from Georgia and Los Angeles Surveillance, Epidemiology, and End Results (SEER) registries with differentiated thyroid cancer diagnosed in 2014 or 2015 were surveyed. Survey data were linked to SEER data on tumor and treatment characteristics. Multivariable logistic regression analysis was performed. MAIN OUTCOME MEASURES: Method of nodule discovery; reason for thyroid surgery. RESULTS: Of patients who underwent surgery, 975 (38.2%) had cancers ≤1 cm, and 1588 cancers (61.8%) were >1 cm. The reported method of nodule discovery differed significantly between patients with cancers ≤1 cm and those with cancers >1 cm (P < 0.001). Cancer ≤1 cm was associated with nodule discovery on thyroid ultrasound (compared with other imaging, OR, 1.59; 95% CI, 1.21 to 2.10), older patient age (45 to 54 years vs ≤44, OR, 1.45; 95% CI, 1.16 to 1.82), and female sex (OR, 1.51; 95% CI, 1.22 to 1.87). Hispanic ethnicity (OR, 0.71; 95% CI, 0.57 to 0.89) and Asian race (OR, 0.67; 95% CI, 0.49 to 0.92) were negative correlates. Cancers ≤1 cm were associated with lower likelihood of surgery for a nodule suspicious or consistent with cancer (OR, 0.48; 95% CI, 0.40 to 0.57). CONCLUSION:Thyroid microcarcinomas are more likely to be detected by ultrasound and less likely to be associated with surgery scheduled for known thyroid cancer. Understanding diagnostic pathways allows for targeted interventions to decrease overdiagnosis and overtreatment.
Authors: Salvatore Vaccarella; Silvia Franceschi; Freddie Bray; Christopher P Wild; Martyn Plummer; Luigino Dal Maso Journal: N Engl J Med Date: 2016-08-18 Impact factor: 91.245
Authors: Manisha Bahl; Julie A Sosa; Rendon C Nelson; Ramon M Esclamado; Kingshuk Roy Choudhury; Jenny K Hoang Journal: World J Surg Date: 2014-06 Impact factor: 3.352
Authors: Louise Davies; Luc G T Morris; Megan Haymart; Amy Y Chen; David Goldenberg; John Morris; Jennifer B Ogilvie; David J Terris; James Netterville; Richard J Wong; Gregory Randolph Journal: Endocr Pract Date: 2015-06 Impact factor: 3.443
Authors: Megan R Haymart; Mousumi Banerjee; Andrew K Stewart; Ronald J Koenig; John D Birkmeyer; Jennifer J Griggs Journal: JAMA Date: 2011-08-17 Impact factor: 56.272
Authors: Sabbir T Rahman; Donald S A McLeod; Nirmala Pandeya; Rachel E Neale; Chris J Bain; Peter Baade; Philippa H Youl; Susan J Jordan Journal: Thyroid Date: 2019-03 Impact factor: 6.568
Authors: Debbie W Chen; David Reyes-Gastelum; Archana Radhakrishnan; Ann S Hamilton; Kevin C Ward; Megan R Haymart Journal: JAMA Surg Date: 2020-10-01 Impact factor: 14.766
Authors: Natalia Arroyo; Katy J L Bell; Vivian Hsiao; Sara Fernandes-Taylor; Oguzhan Alagoz; Yichi Zhang; Louise Davies; David O Francis Journal: J Clin Endocrinol Metab Date: 2022-09-28 Impact factor: 6.134
Authors: Archana Radhakrishnan; David Reyes-Gastelum; Paul Abrahamse; Brittany Gay; Sarah T Hawley; Lauren P Wallner; Debbie W Chen; Ann S Hamilton; Kevin C Ward; Megan R Haymart Journal: J Clin Endocrinol Metab Date: 2022-02-17 Impact factor: 6.134
Authors: Debbie W Chen; David Reyes-Gastelum; Christine M Veenstra; Ann S Hamilton; Mousumi Banerjee; Megan R Haymart Journal: Thyroid Date: 2020-09-22 Impact factor: 6.568